Researchers from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and China Pharmaceutical University presented the discovery of novel orally bioavailable inhibitors of transient receptor potential canonical channels 4 and 5 (TRPC4/5), being developed for the treatment of depression and anxiety.